Amyloid-Journal of Protein Folding Disorders

Papers
(The median citation count of Amyloid-Journal of Protein Folding Disorders is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Changes in the amyloid editorial board members and in editor positions303
A second case of liraglutide-type localised amyloidosis153
Impact of autonomic dysfunction in light chain amyloidosis patient with nephrotic syndrome and cardiac involvement39
Re-evaluation of Mayo 2004 and revised Mayo 2012 staging in patients with AL amyloidosis in the era of new therapies26
Real-world treatment patterns, costs, and outcomes in patients with AL amyloidosis: analysis of the Optum EHR and commercial claims databases24
Commentary to revisiting the genetic epidemiology of ATTRv in Spain: the Balearic Islands as a high-prevalence founder focus24
Comparison between tafamidis and liver transplantation as first-line therapy for hereditary transthyretin amyloidosis23
Characterising diflunisal as a transthyretin kinetic stabilizer at relevant concentrations in human plasma using subunit exchange20
Neurofilament light chain as a biomarker for hereditary ATTR amyloidosis − correlation between neurofilament light chain and nerve conduction study20
A novel transthyretin variant p.Val114Glu (Val94Glu) in an Italian patient with mixed phenotype hereditary transthyretin amyloidosis20
Factors associated with financial toxicity in patients with transthyretin amyloidosis: results from Amyloidosis Research Consortium’s treatment affordability patient and caregiver survey20
Reduction of cardiac AL amyloid deposition after complete response visualised by PiB-PET imaging19
Early cardiovascular autonomic failure in ATTRv predicts poor prognosis and may respond to disease-modifying therapy19
Efficacy of diflunisal for hereditary transthyretin amyloidosis: the Swedish real-world experience19
Role of complementarity-determining regions 1 and 3 in pathologic amyloid formation by human immunoglobulin κ1 light chains17
A clinical and ECG based score to predict incident atrial fibrillation in cardiac amyloidosis: the Amy-Lyon AF score16
Evaluation of the yield index of genetic counselling for first-degree relatives of patients with hereditary transthyretin cardiac amyloidosis15
Clinical impact of beta-blocker withdrawal in transthyretin amyloid cardiomyopathy15
Exploring light chain cardiotoxicity in AL amyloidosis: impact on hiPSC-derived cardiomyocyte activity14
Revisiting the genetic epidemiology of ATTRv in Spain: the Balearic Islands as a high-prevalence founder focus14
Clinical profile and outcome of AA amyloidosis associated kidney disease in India14
Abnormal global longitudinal strain and reduced serum inflammatory markers in cardiac AL amyloidosis patients without significant amyloid fibril deposition14
Human lysozyme inhibits the fibrillation of serum amyloid a protein from systemic AA amyloidosis14
Genetic landscape of hereditary transthyretin amyloidosis in Spain: a multicentric retrospective study14
Identification of epidermal growth factor-containing fibulin-like extracellular matrix protein 1-derived amyloid deposition in a rhesus macaque13
Patients with transthyretin amyloidosis enrolled in THAOS between 2018 and 2021 continue to experience substantial diagnostic delay13
Selective recognition of human small transthyretin aggregates by a novel monoclonal antibody13
Hepatic involvement in light chain amyloidosis: analysis of 130 patients and predictors of hepatic response and survival13
Clarifying the immunoglobulin light chain variable gene usage in Chinese patients with renal AL amyloidosis12
Guidelines for the management of hereditary ATTR amyloidosis 202612
Frontline Dara-CyBorD for AL amyloidosis: high response rates and cytogenetic insights from a real-world cohort12
Serum neurofilament light chain in hereditary transthyretin amyloidosis: validation in real-life practice12
Left atrioventricular coupling index assessed with three-dimensional echocardiography: a prognostic marker of short-term outcomes in light-chain cardiac amyloidosis12
Electric field-induced destabilization and surface modulation of Aβ42 fibrils in molecular simulations: theoretical implications for direct current stimulation in Alzheimer’s disease12
Mapping cellular response to destabilized transthyretin reveals cell- and amyloidogenic protein-specific signatures12
Refining prognostication in systemic AL amyloidosis: limited value of dFLC11
Brain MRI in patients with V30M hereditary transthyretin amyloidosis10
ALyzer3D.AI: a more generalizable deep learning predictor of light chain amyloidogenicity powered by structural and evolutionary Artificial Intelligence10
Clinical and molecular insights into A97S variants in hereditary transthyretin amyloid polyneuropathy in South China10
Whole tissue proteomic analyses of cardiac ATTR and AL unveil mechanisms of tissue damage9
Amyloid nomenclature 2024: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee9
Possible transmission of leukocyte chemotactic factor 2 amyloidosis after interpopulational liver transplantation9
Accelerated apolipoprotein A-II senile amyloidosis in a plasminogen activator inhibitor-1 knock-out model8
Change of guard at Amyloid – a tribute to outgoing Editor in Chief, Professor Per Westermark8
Complete remission after patisiran treatment in a patient with nephrotic syndrome secondary to hereditary transthyretin amyloidosis (ATTR)7
Involvement of bile acid in diarrhoea and therapeutic effect of colestimide in hereditary ATTR amyloidosis7
RNA-based full length immunoglobulin light chain sequencing reveals lambda constant domain mutations with potential implications for thermodynamic stability in light chain amyloidosis7
Fewer gastrointestinal events with vutrisiran versus placebo in patients with transthyretin amyloidosis with cardiomyopathy: analysis from the phase 3 HELIOS-B study7
Cold pressor test and paradoxical blood pressure reduction in light chain amyloidosis7
AA amyloidosis as an adverse event of immune checkpoint inhibitor therapy: evidence from the FDA adverse event reporting system and a systematic review7
A rare occurrence and near miss! Should a TTR gene test be routinely performed for suspected ATTR-cardiomyopathy?7
Serum peripherin as a disease biomarker in hereditary transthyretin amyloidosis: a multicenter cohort study7
Longitudinal analysis of serum neurofilament light chain levels as marker for neuronal damage in hereditary transthyretin amyloidosis7
Incidence of second primary malignancies in patients with AL amyloidosis and the impact of disease stage and therapies7
Predictors of cognitive dysfunction in hereditary transthyretin amyloidosis with liver transplant7
Correction7
Incidence and predictors of sudden death in patients with cardiac amyloidosis6
Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study6
Single-slide detection and typing of AL renal amyloidosis: combining mass spectrometry imaging and digital pathology6
Subtyping of cardiac amyloidosis by mass spectrometry-based proteomics of endomyocardial biopsies6
Prognostic impact of cardiac resynchronization therapy in wild-type transthyretin amyloid cardiomyopathy6
Altered connectivity of central autonomic network: effects of dysautonomia in hereditary transthyretin amyloidosis with polyneuropathy6
Enhanced analytic methodology enables postmortem diagnosis of hereditary AApoAI amyloidosis6
Proteostasis is disrupted in human endothelial cells by serum from ATTR patients and is rescued by tafamidis treatment6
Right ventricular coupling predicts cardiopulmonary fitness in cardiac transthyretin amyloidosis6
Neuropathy progression in hereditary transthyretin amyloidosis (ATTRv) patients after liver transplantation6
Reduction in 99m Tc-DPD myocardial uptake with therapy of ATTR cardiomyopathy5
In memoriam: Shukuro Araki, MD, PhD (1927–2025) pioneer of Japanese neurology and a global leader in familial amyloid polyneuropathy5
Interactions between amyloid fibril proteins5
Limited diagnostic utility of systematic Congo red staining in bone marrow biopsies5
Heterogeneity in families with ATTRV30M amyloidosis: a historical and longitudinal Portuguese case study impact for genetic counselling5
Detection of ATTR aggregates in the plasma of polyneuropathic patients with ATTR-V30M amyloidosis5
Proline-rich, polybasic peptides are a structurally distinct class of amyloid-reactive peptides4
Computed tomography-derived myocardial radiomics for detection of transthyretin amyloidosis in patients with severe aortic stenosis4
Echocardiographic findings in subjects with an amyloidogenic apolipoprotein A1 pathogenic variant4
Amyloid myopathy in the internal oblique muscle of patients with wild-type transthyretin cardiac amyloidosis4
The way to a man’s heart: prostate samples for the early detection of transthyretin cardiomyopathy4
Technetium-99m-pyrophosphate imaging-based computed tomography-guided core-needle biopsy of internal oblique muscle in wild-type transthyretin cardiac amyloidosis4
A collaborative approach to amyloidosis and a multidisciplinary care framework – position statement from the International Society of Amyloidosis4
The impact of Post-Transplant doxycycline in AL amyloidosis – updated results after Long-Term follow up4
Long-term efficacy and safety of vutrisiran in hereditary transthyretin amyloidosis with polyneuropathy: final analysis of the HELIOS-A randomized treatment extension4
High frequency of occult transthyretin and apolipoprotein AI–type amyloid in aortic valves removed by valve replacement for aortic stenosis4
A comparison of single versus combination mechanism treatment for transthyretin amyloid cardiomyopathy4
High rate of false negative 99m Tc-pyrophosphate scintigraphy scans in patients with Leu58His transthyretin amyloid cardiomyopathy4
Diagnostic and prognostic contribution of DPD scintigraphy in transthyretin V30M cardiac amyloidosis4
Global patterns of amyloid typing: results of a survey by the International Society of Amyloidosis (ISA)3
Regarding the challenges of amyloidosis diagnosis and typing in Ukraine3
Hereditary transthyretin amyloidosis with cardiomyopathy and polyneuropathy associated with a novel pathogenic TTR Tyr105His (p.Tyr125His) mutation3
AA amyloidosis in vertebrates: epidemiology, pathology and molecular aspects3
Relationship of binding-site occupancy, transthyretin stabilisation and disease modification in patients with tafamidis-treated transthyretin amyloid cardiomyopathy3
A cautionary case series: tafamidis mistreatment following erroneous diagnosis of transthyretin cardiac amyloidosis3
Internalisation of immunoglobulin light chains by cardiomyocytes in AL amyloidosis: what can biopsies tell us?3
PRX004 in variant amyloid transthyretin (ATTRv) amyloidosis: results of a phase 1, open-label, dose-escalation study3
Quantitative sensory testing: a good tool to identify subclinical neuropathy in ATTRV30M amyloidosis patients?3
Usefulness of the Columbia score for predicting outcomes in patients with transthyretin amyloid cardiomyopathy. Analysis of the Galician registry of cardiac amyloidosis3
ATTR- and AFib amyloid - two different types of amyloid in the annular ligament of trigger finger3
Longitudinal PET/CT imaging with iodine ( 124 I) evuzamitide reveals organ response to plasma cell immunotherapy in a patient with AL amyloidosis3
Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee3
The role of cardiac imaging for diagnosis of cardiac amyloidosis: a systematic review and meta-analysis of test accuracy3
Functional and morphometric assessment of small-fibre damage in late-onset hereditary transthyretin amyloidosis with polyneuropathy: the controversial relation between small-fibre-related symptoms and2
Hepatic multimodal phenotyping in AL amyloidosis with cardiac involvement: the D-Amy-LIPHE study2
Mass spectrometry-based proteomic analysis of proteins adsorbed by hexadecyl-immobilized cellulose bead column for the treatment of dialysis-related amyloidosis2
Transthyretin monomers: a new plasma biomarker for pre-symptomatic transthyretin-related amyloidosis2
XIX International Symposium on Amyloidosis Abstracts2
Hereditary transthyretin amyloidosis in middle-aged and elderly patients with idiopathic polyneuropathy: a nationwide prospective study2
The CATCH-ATTR study: CArpal Tunnel ligament amyloid—the Clue for early identification of Hereditary or wildtype systemic ATTR amyloidosis?2
Significance of aberrant nerve conduction in hereditary transthyretin amyloidosis2
Identification of calcitonin receptor-stimulating peptide 1-derived amyloid in a feline C-cell carcinoma2
Correlation of 99mTc-DPD bone scintigraphy with histological amyloid load in patients with ATTR cardiac amyloidosis2
Genetic counselling for at-risk family members with hereditary transthyretin amyloidosis: data from a single-centre study2
Hereditary gelsolin amyloidosis: a rare cause of cranial, peripheral and autonomic neuropathies linked to D187N and Y447H substitutions2
Binding of serum-derived amyloid-associated proteins to amyloid fibrils2
Optimized methods for efficient application of immunogold electron microscopy to amyloid fibrils typing2
No body fits in the test tube – the case of transthyretin2
Development and validation of the modified-comprehensive Kumamoto Score: a multi-organ assessment tool for hereditary transthyretin amyloidosis2
A report from the European Proteomics Amyloid Network (EPAN)2
The flutemetamol analogue cyano-flutemetamol detects myocardial AL and ATTR amyloid deposits: a post-mortem histofluorescence analysis2
Prognostic value of CMR-derived extracellular volume in AL amyloidosis: a multicenter study1
A phase 1b dose-escalation study of carfilzomib in combination with thalidomide and dexamethasone in patients with relapsed/refractory systemic immunoglobulin light chain amyloidosis1
Correction1
Impact of tafamidis on myocardial strain in transthyretin amyloid cardiomyopathy1
T2-relaxometry in a large cohort of hereditary transthyretin amyloidosis with polyneuropathy1
Iatrogenic cerebral amyloid angiopathy rather than sporadic CAA in younger adults with lobar intracerebral haemorrhage1
Rare-variant collapsing and bioinformatic analyses for amyloidosis, dementia and Parkinson’s disease in the UK biobank reveal novel susceptibility loci1
Collagen inhibits phagocytosis of amyloid in vitro and in vivo and may act as a ‘don’t eat me’ signal1
Patient-reported outcome measures for transthyretin cardiac amyloidosis: the ITALY study1
Patient-reported satisfaction with telemedicine in light chain (AL) amyloidosis care1
Outcomes of venetoclax-based therapy in patients with t(11;14) light chain amyloidosis after failure of daratumumab-based therapy1
Impact of autonomic dysfunction on cardiovascular outcomes among patients with ATTR cardiomyopathy: insights from the COMPASS-311
How well does liver span as part of the consensus criteria for liver involvement in AL amyloidosis perform?1
Prognostic role of cardiopulmonary exercise testing in wild-type transthyretin amyloid cardiomyopathy patients treated with tafamidis1
Looking beyond left ventricular wall thickness: the search for cardiac amyloidosis in women1
Prevalence of amyloid in ligamentum flavum of patients with lumbar spinal stenosis1
Right ventricular-pulmonary arterial coupling and outcomes in cardiac amyloidosis: systematic review and meta-analysis1
In memoriam: Lawreen Connors, Ph.D.1
Detection yield of surrogate tissue biopsies across amyloidosis classes: a large-scale analysis of 4,027 patients1
Previous surgery for lumbar spinal stenosis and association with amyloidosis and heart failure – A Danish nationwide study1
Neuropathy impairment and nutritional status with eplontersen in patients with hereditary transthyretin-mediated amyloidosis1
Dual AApoAIV amyloidosis and ATTR amyloidosis arising in the same patient: a report of three cases1
Medin and transthyretin: a new amyloid double act in the aortic wall and valves1
Fluorine-18 florbetapir positron emission tomography unmasks amyloidosis with equivocal technetium-99m pyrophosphate findings driven by a novel transthyretin variant1
Early cardiac sympathetic denervation in hereditary transthyretin amyloidosis: 123 I-metaiodobenzylguanidine findings and correlation with skin biops1
Proteolysis reconciles inconsistencies found in proteomic and cryo-EM studies of ATTR1
Cardiac amyloidosis: the possibilities and challenges in the Ghanaian setting1
Delayed identification of monoclonal protein is associated with early death in isolated cardiac AL amyloidosis1
Neurofilament light chain kinetics as a biomarker for polyneuropathy in V122I hereditary transthyretin amyloidosis1
Distribution and progression of cerebral amyloid angiopathy in early-onset V30M (p.V50M) hereditary ATTR amyloidosis1
Obituary1
Absence of an increased wall thickness does not rule out cardiac amyloidosis1
Circulating transthyretin and retinol binding protein 4 levels among middle-age V122I TTR carriers in the general population1
Decreased expression of S100A8/A9 in V30M related ATTRv amyloidosis1
0.15804004669189